Field Guide · Deconstructed
This one is easy to confuse, so let’s be precise up front. This is not IVIG — not the big intravenous infusion that floods the whole bloodstream. This is local: immunoglobulins (antibodies) delivered right into the nasal mucosa — usually a compounded nasal preparation — to neutralize microbes and toxins at the gateway and shore up the nose’s own defense. Why the nose, of all places? Because in PANS the nose isn’t a sinus problem. It’s a doorway to the brain, and a reservoir that keeps the immune system lit. Here’s the mechanism, where it fits, and exactly how early the evidence still is.
I walked this part of the labyrinth myself — knocked on the doors, read the research, and came back with the map. You don’t have to find the way out alone.
Intranasal immunoglobulin is antibody protein applied directly to the lining of the nose. Two kinds matter: IgG (the workhorse neutralizing antibody) and secretory IgA (the antibody the mucosa makes for itself, its frontline guard). Sprayed or instilled into the nostrils, they coat the mucosa, bind microbes and toxins at the entry point, and reinforce local defense — so fewer triggers ever get a foothold. It is emphatically NOT IVIG: IVIG is a systemic, whole-body infusion through a vein. This is small, local, and aimed at one specific place — the nasal gateway. Different tool, different scale, different purpose.
Most parents think of the nose as plumbing. In PANS it’s two things that matter much more — and intranasal immunoglobulin is aimed at both.
(a) The olfactory route — the nose is a direct doorway to the brain. This is the part the field is only now absorbing. Dr. Dritan Agalliu’s lab at Columbia showed, in mouse models, that repeated strep in the nose sends strep-specific Th17 immune cells migrating along the olfactory nerves — up through the cribriform plate — straight into the brain, where they crack open the blood-brain barrier and let autoantibodies in, driving neuroinflammation and odor-processing deficits. The nose isn’t near the brain incidentally; it’s a highway to it. That reframes nasal treatment entirely: clean up the doorway, and you may be closing the road the inflammation travels. Sources: Dileepan et al., JCI 2016 (intranasal strep → Th17 into CNS) · Platt et al., PNAS 2020 (Th17 open the BBB to autoantibodies) · Columbia / Agalliu summary.
(b) Nasal pathogen reservoirs — the nose keeps the fire lit. The deep nasal passages can harbor chronic, biofilm-protected colonization that the immune system never fully clears — classically MARCoNS (multiply-antibiotic-resistant coagulase-negative staph), the bug Dr. Ritchie Shoemaker tied to chronic biotoxin illness and suppressed MSH. A reservoir like this is a standing source of trigger, day after day. Treating the nose addresses both the doorway and the reservoir. Sources: MicrobiologyDX — about MARCoNS · Surviving Mold — MARCoNS Q&A.
The mechanism is simple to picture, which is part of its appeal — it works at the surface, not through the bloodstream.
The logic, in one line: fewer triggers at the gate → less reaching the doorway to the brain → a quieter immune system.
Intranasal immunoglobulin is one tool among several, and like everything in the nose, order matters. You don’t just layer it on top of an unaddressed colonization — you deal with the reservoir and the biofilm first or alongside, then use Ig to hold the ground. Here is the broader kit it sits inside.
| Tool | What it does — and where Ig fits |
|---|---|
| The nasal workup MARCoNS panel | You test before you treat. A deep-nasal MARCoNS culture tells you whether a resistant, biofilm-protected reservoir is actually there — the thing that keeps the immune system lit. Map the territory first. |
| Shoemaker BEG spray compounded antibiotic | The classic compounded spray (Bactroban/EDTA/Gentamicin) aimed at clearing MARCoNS and the biofilm that shields it. This is reservoir-clearing — the step that opens the ground for everything after. |
| Biofilm-aware irrigation EDTA / xylitol / Xlear | Biofilm is the armor; you have to disrupt it for anything to reach the bug. Xylitol (Xlear) and EDTA-based rinses help keep the passages hostile to recolonization — a maintenance layer. |
| Intranasal immunoglobulin IgG + secretory IgA | This entry. Once the reservoir is being cleared, Ig coats and defends the cleaned surface — neutralizing what tries to re-establish and reinforcing local immunity. It holds the ground, it doesn’t clear it alone. |
| VIP nasal spray Shoemaker capstone | Vasoactive Intestinal Polypeptide, the final repair step in the Shoemaker sequence — only after exposure is gone, MARCoNS is cleared, and the inflammatory picture has settled. Last, not first. |
The order rule, said plainly: don’t spray immunoglobulin onto an active, biofilm-protected colonization and expect it to fix things. Clear (or actively be clearing) the reservoir and biofilm first or alongside — then use Ig to defend the cleaned surface. Layering it on blind, out of sequence, is the common mistake. The nose rewards sequence and punishes shortcuts — the same lesson as the whole mold protocol.
Be clear-eyed here, because the two halves of this are at very different stages.
The olfactory-route SCIENCE is real and published. Agalliu’s nasal-strep-to-brain pathway is peer-reviewed work in JCI and PNAS — it is genuine, mechanistic, and increasingly cited. The reason the nose matters in PANS is not speculative.
The nasal-immunoglobulin APPLICATION is early. Using intranasal IgG/IgA as a PANS treatment is emerging, compounded, and practitioner-level — not a standardized, trial-proven therapy. There’s real precedent for delivering immunoglobulin to the airway (nebulized and intranasal Ig has been studied for chronic sinus and immune-deficiency contexts), but a randomized PANS trial of nasal Ig does not exist. Sources: Immunoglobulins in nasal secretions, rhinitis & chronic rhinosinusitis (PubMed) · Chronic sinusitis controlled with enriched immunoglobulins (case report).
So the honest framing: intranasal immunoglobulin is a reasonable, low-aggression tool in the nasal toolkit for the right child — the mechanism is sound and the local approach is gentle — but it is not a cure, and not proven. It tends to be tried when the doorway and reservoir are the suspected problem and gentler reinforcement is wanted; it can help hold a cleaned nose. Frame it as a question to bring your practitioner, not a settled answer.
Start at the top and follow your child. Tap to open.
Recurrent strep, chronic congestion, frequent sinus issues, or flares that track with nasal/respiratory triggers → the nose is worth investigating. Start with the nasal workup — a MARCoNS panel — before treating anything. Map first.
Yes → clear it first or alongside (BEG spray, biofilm-aware irrigation). Then immunoglobulin holds the cleaned ground. No clear reservoir, but a reactive/triggered nose → Ig can be a gentle reinforcement — introduced low and slow.
Then mind the source — bovine-derived preparations carry a protein-reactivity caveat. Introduce gently, one variable at a time, and watch closely. A reactive mucosa at the doorway to the brain deserves extra patience.
That’s the hard part — nasal work has to be sequenced against everything else (infections, mold, the methylation/drainage engine). That’s exactly what Minta holds. See below.
This is a lot — and you don’t have to read it alone. Minta takes your child’s nasal workup, infection picture, and the rest of their labs and daily symptoms, and tells you where in the sequence you are — whether a reservoir needs clearing first, where immunoglobulin reinforcement fits, and what to watch in a reactive kid — then walks each step with you. The doorway-and-reservoir read no single specialist sits down and makes. Let Minta sequence this with you →
Credentials, polish, and how conventional an approach sounds tell you little about whether a practitioner will help your child — or harm them. What does: their behavior and their incentives. Watch those.
Intranasal immunoglobulin is antibody applied right in the nose — not IVIG, not a systemic infusion — aimed at the two things that make the nose matter in PANS: it’s a doorway to the brain (the published Agalliu olfactory route) and a reservoir that keeps the immune system lit (MARCoNS, biofilm). It works by coating the mucosa, binding triggers at the gate, and reinforcing the nose’s own secretory-IgA defense — so fewer triggers ever reach the brain. The mechanism is sound and the approach is gentle; the application is emerging, compounded, and practitioner-level, not proven — a reasonable, low-aggression tool in the nasal kit, not a cure. Clear the reservoir first or alongside, mind the source in reactive kids, and introduce low and slow. Bring it to your team as questions, not instructions. This is parent education, not medical advice.
Plan B does not partner with drug companies or doctors, and we never endorse anyone whose healing isn’t verified by families. We show you the options and how to vet them yourself — and we’re building parent verification: look up a practitioner and see real family reviews before you trust them. Universal bad reviews? Skip.